Subvolts take Montana opens market for experimental drugs bypassing FDA, attracting longevity investors. Aug 4, 2026 - Developers
- This policy change creates a new, less regulated pathway for biotech product development and market entry.
- Business
- Companies can now potentially reach consumers faster with experimental treatments, bypassing traditional regulatory hurdles.
- Everyday users
- You may gain earlier access to experimental medicines, but with potentially unproven safety and efficacy.
This policy change allows experimental drugs to reach consumers without FDA approval, altering access to new treatments.
Biohackers head to Big Sky Country
Good morning, tech enthusiasts. Montana just put experimental medicine on the open market. For a $12,500 fee and a Phase I safety readout, any biotech company can clear a private review board, set its own price, and sell straight to patients — no terminal diagnosis required, no FDA review. The first clinics open by December, and Silicon Valley’s longevity set is already lining up. The Rundown: Montana is reportedly set to become Silicon Valley’s biotech and longevity playground — a state where startups sell experimental drugs directly to consumers, set their own prices, and move around the FDA entirely.
Opening of the original on The Rundown AI From Subvolts
Summary and analysis by Subvolts editorial, AI-assisted.
Montana now allows biotech companies to sell experimental medicine directly to consumers without FDA review. For a $12,500 fee and a safety readout, companies can bypass traditional regulatory paths. This move positions the state as a potential hub for Silicon Valley's longevity and biohacking industries, with clinics opening by December.
Montana has created a new market where companies can sell experimental drugs directly to people without FDA approval. For a fee, companies can bypass the usual safety reviews. This could attract investors interested in longevity and biohacking, with clinics expected to open soon.
Montana's new law creates a regulatory loophole for experimental drugs, bypassing the FDA. This directly impacts consumers seeking unapproved treatments and biotech startups looking for faster market access. It contrasts sharply with the rigorous FDA process other countries and US states follow. Future watch: Monitor patient outcomes and the number of companies utilizing this pathway. The long-term safety and efficacy of these drugs will be critical.
- Location: Montana
- Fee: $12,500
- Requirement: Phase I safety readout
- Regulatory bypass: No FDA review
- Clinic opening: December
- Phase I safety readout
- The results of the first stage of clinical trials, focused on assessing the safety and dosage of a new drug in a small group of humans.
- Early safety test results from human trials.
- longevity set
- A group of individuals, often from the tech industry, interested in and investing in technologies and practices aimed at extending human lifespan and healthspan.
- People focused on extending life and health.
The Playbook: reusable how-tos, prompts, configs and tips pulled out of the news. From the Playbook, matched to the product and topics of this item.
- RuleLimit initial Grok Bot tests to fictional messages and your own addressStart Grok Bot testing with fictional messages and your own email to avoid unintended external communication. · 5 min
- RuleSet Grok Bot to ask before sending or forwarding emailConfigure Grok Bot to request confirmation before sending or forwarding any email to prevent errors. · 2 min
- ChecklistReview AI-generated project update drafts before sendingCheck AI-drafted project updates for accuracy, completeness, and correct dates before sending. · 5 min
- TemplateGuide for teens using AI responsiblyA document to help teens understand and use AI tools safely and effectively. · 15 min
Questions people ask
- What is Montana's new policy for experimental medicine?
- Montana allows biotech companies to sell experimental medicine directly to patients for a fee, bypassing FDA review.
- What are the requirements for companies?
- Companies need to pay a $12,500 fee and provide a Phase I safety readout.
- When will clinics open?
- The first clinics are expected to open by December.
More from The Rundown AI 3 more
Page generated Oct 19, 2026. Summaries are Subvolts' own; the story belongs to The Rundown AI.